Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.

Background And Objectives: Early treatment of multiple sclerosis (MS) reduces disease activity and the risk of long-term disease progression. Effectiveness of ocrelizumab is established in relapsing MS (RMS); however, data in early RMS are lacking. We evaluated the 4-year effectiveness and safety of ocrelizumab as a first-line therapy in treatment-naive patients with recently diagnosed relapsing-remitting MS (RRMS).

Reversible posterior leukoencephalopathy syndrome (RPLS) in a patient with chronic lymphocytic leukemia (CLL) treated with Acalabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor: a case report.

RPLS is a rare neuroradiologic syndrome characterized by headache, visual disturbances, focal deficits and confusion. There are several underlying mechanisms causing RPLS, including arterial hypertension and renal failure, but also treatments with immunosuppressive therapy, chemotherapy or targeted therapy (such as small molecule inhibitors). Acalabrutinib is a novel second-generation BTK inhibitor, frequently used as treatment for B-cell malignancies.

Evaluating pain management practices for cancer patients among health professionals in cancer and supportive/palliative care units: a Belgian survey.

Background: Pain is reported in 66% of cancer patients with advanced disease. Adequate pain management is a cornerstone of comprehensive supportive cancer care.

Purpose: The purpose of this study was to assess pain management in Oncology Units in Belgium.

Measuring the diagnostic management and follow-up imaging for glioma patients across Belgian hospitals between 2016 and 2019.

Objectives: This study aimed to assess the diagnostic management and follow-up imaging for glioma patients across Belgian hospitals by calculating process indicators.

Methods: Patients with newly diagnosed glioma in Belgium (2016-2019) were selected from the Belgian Cancer Registry. The National Social Security Number served as unique patient identifier, linking the Registry to vital status and reimbursement data.

A 36-Year-Old Man with Persistent Headache.

AbstractMorning Report is a time-honored tradition where physicians-in-training present cases to their colleagues and clinical experts to collaboratively examine an interesting patient presentation. The Morning Report section seeks to carry on this tradition by presenting a patient's chief concern and story, inviting the reader to develop a differential diagnosis and discover the diagnosis alongside the authors of the case. This report examines the story of a 36-year-old man who sought evaluation for a persistent headache and numbness on the cheek.